- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- LMG324, Ranibizumab 0.5 mg, Sham
- Biological
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 90
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Macular Edema
- Interventions
- LKA651, Lucentis
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
- Conditions
- Macular Edema, Diabetic
- Interventions
- Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
- Conditions
- Fibrovascular Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Degeneration
- Interventions
- abicipar pegol, ranibizumab, sham procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
- Interventions
- FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- Drug
- Lead sponsor
- Formycon AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Campbell, California • Long Beach, California • Hagerstown, Maryland + 1 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Efalizumab, Ranibizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • San Diego, California • Torrance, California + 7 more
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
- Interventions
- OPT-302, Lucentis™
- Drug
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
- Other · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Retinal Vein Occlusion, Macular Edema
- Interventions
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Uveitis, Cytoid Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Macular Degeneration
- Interventions
- bevasiranib, ranibizumab
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
- Conditions
- Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
- Interventions
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Houston, Texas • Katy, Texas • The Woodlands, Texas
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser
- Drug · Behavioral · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 56
- States / cities
- Artesia, California • Beverly Hills, California • Irvine, California + 46 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Device · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 52
- States / cities
- Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 47 more
- Conditions
- Von Hippel-Lindau Syndrome
- Interventions
- Ranibizumab, E10030
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-related Macular Degeneration
- Interventions
- AGN-150998, ranibizumab, Sham Injection
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Age-Related Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion
- Interventions
- Ranibizumab, Peripheral Laser
- Drug · Procedure
- Lead sponsor
- Retina Associates of Florida, P.A.
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- verteporfin, ranibizumab, dexamethasone
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
- Conditions
- Diabetic Macular Edema
- Interventions
- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 89
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more